Fig. 3: Tumor response and survival outcomes. | Nature Communications

Fig. 3: Tumor response and survival outcomes.

From: Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial

Fig. 3

Waterfall plot showing the maximum percent change in tumor-targeted lesion size from baseline in each patient as measured by the Response Evaluation Criteria in Solid Tumors (A). The upper dashed line indicates a 20% increase in the tumor burden (PD), and the lower dashed line indicates a 30% decrease in the tumor burden (PR). Asterisks indicate the presence of a new lesion. The Kaplan–Meier curve for progression-free survival (PFS) (B) and overall survival (OS) (C). The data cut-off date for clinical activity was August 20, 2024, and the median follow-up interval was 33.3 months. Vertical lines denote censored patients. The blue area shows the 95% confidence intervals (CI) for the PFS and OS curves. Source data are provided as a Source Data file.

Back to article page